Our Services
Medical Information
Helpful Resources
Published on: 9/15/2026
Most people notice early side effects such as dizziness, headache, nausea, drowsiness, or mild unsteadiness during the first days to two weeks of each dose increase, and these often fade as the body adapts. Because lamotrigine must be titrated slowly to lower the risk of serious rash, the standard ramp-up takes about 5 to 6 weeks to reach a starting target dose, with full mood-stabilizing or seizure-control benefits sometimes taking 6 weeks to 3 months to become clear. Timelines shift depending on your dose, whether you also take valproate or carbamazepine, kidney and liver function, and personal sensitivity, and any spreading rash, fever, swelling, or blistering warrants urgent medical attention rather than waiting it out. There are several important factors and warning signs to consider, so see below to understand more.
If you are unsure whether what you feel is a normal adjustment period or something that needs prompt attention, a few minutes of structured self-assessment can bring real clarity. Take a free, instant, online symptom check to sort your symptoms, see what may be driving them, and get guidance on the right next steps and when to contact a clinician.
Last reviewed for medical accuracy: 09/15/2025
Lamotrigine is a prescription medication most often used to treat epilepsy (seizure disorders) and bipolar disorder (mood swings, depression). Because it works by stabilizing electrical activity in the brain, your body needs time to get used to it. Below, we cover what to expect during the adjustment period, typical timelines, common side effects, and practical tips for making the transition smoother.
Lamotrigine carries a risk of a serious skin reaction (Stevens-Johnson syndrome) if doses increase too quickly. To lower that risk and help your system adapt, doctors follow a careful titration schedule. This means starting with a low dose and gradually increasing it over several weeks.
While your doctor will tailor the plan to your needs, a common approach for adults is:
Week
• Week 1–2: 25 mg once daily
• Week 3–4: 50 mg once daily
• Week 5: 100 mg once daily
• Week 6: 150 mg once daily
• Week 7 and beyond: 200 mg once daily (maintenance dose)
If you’re taking other medications (e.g., valproate), or if you have liver or kidney issues, your doctor may slow the increases even more.
Initial Phase (Weeks 1–2)
• You may notice very mild relief of mood swings or fewer mild seizures, but it’s still early.
• Side effects like headache or dizziness often show up now.
Middle Phase (Weeks 3–6)
• Many people begin to feel clearer thinking and more mood stability around weeks 4–6.
• Seizure frequency can decline noticeably if you’re taking it for epilepsy.
• Side effects generally peak in this stage, then start to taper off.
Maintenance Phase (After Week 7)
• Full therapeutic benefits typically appear by weeks 8–12.
• Side effects that haven’t resolved by week 8 should be discussed with your doctor.
• Once you’re on a steady dose, most people feel stable and can notice ongoing mood or seizure control.
In total, most people adjust within 6–12 weeks. Individual responses vary, so your timeline might be a bit shorter or longer.
Almost everyone experiences some side effects at first. These often lessen over time:
• Dizziness or unsteadiness
• Headache
• Sleep changes (insomnia or drowsiness)
• Nausea or upset stomach
• Blurred vision or double vision
• Irritability or mood swings
If you experience a rash, swelling of the face or throat, or any breathing difficulties, stop taking lamotrigine and seek medical attention immediately. These can be signs of a severe reaction.
• Take lamotrigine at the same time every day, with or without food.
• Keep a daily journal to track mood, seizures, sleep, and side effects.
• Stay hydrated and maintain a balanced diet to support overall health.
• Avoid alcohol during dose increases—it may worsen side effects.
• Don’t skip doses. If you miss one, take it as soon as you remember unless it’s close to your next dose.
• Communicate regularly with your doctor about what you’re feeling.
Lamotrigine adjustment usually goes smoothly, but you should contact your doctor if you experience:
• Any rash, even if mild
• High fever, swollen glands, or joint pain
• Thoughts of self-harm or worsening depression
• Severe dizziness, confusion, or coordination problems
• New or worsening seizures
If you ever feel that your symptoms might be life-threatening or you’re unsure what to do, please speak to a doctor right away.
For non-urgent questions about your symptoms, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you decide if you need to seek in-person care.
• Patience is key. Adjusting to lamotrigine is not instant.
• Improvement often comes in stages—some days will feel better than others.
• Side effects usually decrease after 4–6 weeks.
• Your doctor may alter the schedule if you have other health conditions or medications.
Adjusting to lamotrigine takes time—typically 6–12 weeks to reach a stable, effective dose. Side effects are common at first but tend to fade. By following a slow titration schedule, keeping track of how you feel, and staying in close touch with your healthcare provider, you’ll give yourself the best chance for a smooth transition.
If you have any worrying symptoms or feel unsure about your progress, don’t hesitate to speak to a doctor. Remember, professional guidance is essential for safe and effective treatment.
(References)
* Sarzi-Puttini P, Panni B, Cazzola M, Muzzupappa S, Turiel M. Lamotrigine-induced lupus. Lupus. 2000;9(7):555-7. doi: 10.1177/096120330000900715. PMID: 11035425.
* Hilas O, Charneski L. Lamotrigine-induced Stevens-Johnson syndrome. Am J Health Syst Pharm. 2007 Feb 1;64(3):273-5. doi: 10.2146/ajhp060071. PMID: 17244876.
* Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, Sabers A, Thomas SV, Vajda F, EURAP Study Group. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018 Jun;17(6):530-538. doi: 10.1016/S1474-4422(18)30107-8. Epub 2018 Apr 18. PMID: 29680205.
* Marson AG, Burnside G, Appleton R, Smith D, Leach JP, Sills G, Tudur-Smith C, Plumpton CO, Hughes DA, Williamson PR, Baker G, Balabanova S, Taylor C, Brown R, Hindley D, Howell S, Maguire M, Mohanraj R, Smith PE. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Health Technol Assess. 2021 Dec;25(75):1-134. doi: 10.3310/hta25750. PMID: 34931602.
* Dreier JW, Bjørk MH, Alvestad S, Gissler M, Igland J, Leinonen MK, Sun Y, Zoega H, Cohen JM, Furu K, Tomson T, Christensen J. Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders. JAMA Neurol. 2023 Jun 1;80(6):568-577. doi: 10.1001/jamaneurol.2023.0674. PMID: 37067807; PMCID: PMC10111234.
* Cerulli Irelli E, Cocchi E, Morano A, Gesche J, Caraballo RH, Lattanzi S, Strigaro G, Catania C, Ferlazzo E, Pascarella A, Casciato S, Quarato P, Pizzanelli C, Pulitano P, Giuliano L, Viola V, Mostacci B, Fortunato F, Marini C, Di Gennaro G, Gambardella A, Labate A, Operto FF, Giallonardo AT, Baykan B, Beier CP, Di Bonaventura C, Women With Epilepsy Treatment Options and Research (WETOR) Study Group. Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy. JAMA Neurol. 2023 Nov 1;80(11):1174-1181. doi: 10.1001/jamaneurol.2023.3400. PMID: 37782485; PMCID: PMC10546294.
* Ishikawa R, Iseki M. [Pharmacological Treatment of Trigeminal Neuralgia]. No Shinkei Geka. 2024 Jan;52(1):63-69. doi: 10.11477/mf.1436204880. PMID: 38246671.
* Hernández-Díaz S, Straub L, Bateman BT, Zhu Y, Mogun H, Wisner KL, Gray KJ, Lester B, McDougle CJ, DiCesare E, Pennell PB, Huybrechts KF. Risk of Autism after Prenatal Topiramate, Valproate, or Lamotrigine Exposure. N Engl J Med. 2024 Mar 21;390(12):1069-1079. doi: 10.1056/NEJMoa2309359. PMID: 38507750; PMCID: PMC11047762.
* Barnard SN, Chen Z, Kanner AM, Holmes MG, Klein P, Abou-Khalil BW, Gidal BE, French J, Perucca P, Human Epilepsy Project. The Adverse Effects of Commonly Prescribed Antiseizure Medications in Adults With Newly Diagnosed Focal Epilepsy. Neurology. 2024 Oct 8;103(7):e209821. doi: 10.1212/WNL.0000000000209821. Epub 2024 Sep 13. PMID: 39270150.
* Ng SCW, Hernandez-Diaz S, Quinn M, Ward JR, Conant S, Lyons A, High FA. Antiseizure Medication Polytherapies During Pregnancy and the Risk of Congenital Malformations. Neurology. 2026 Jun 9;106(11):e214984. doi: 10.1212/WNL.0000000000214984. Epub 2026 May 7. PMID: 42096673.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.